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Edited by Irmgard SinningAbstract In this study, we describe the cloning and the
characterization of the third FMRFamide-related peptide
(FaRP) receptor in Caenorhabditis elegans, the VRFa receptor
1. Numerous structurally diﬀerent FaRPs were synthesized and
used to screen the orphan C26F1.6 receptor for activation. Two
peptides ending in M(orL)VRFamide elicited a calcium response
in receptor expressing mammalian cells. The response is dose-
dependent and appeared to be very speciﬁc, since very closely
related FaRPs were less active, even the other peptides ending in
M(orL)VRFamide. Pharmacological proﬁling of the most active
peptide suggests that SMVRFa is the most active binding core.
N-terminal extension decreases peptide activity.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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For a variety of reasons, the nematode worm Caenorhabditis
elegans has been developed into a prime model system in an-
imal biology. In 2002, the Nobel Prize for Medicine/Physiol-
ogy was awarded to the pioneers in this domain, namely
Brenner, Horvitz and Sulston.
The C. elegans genome (97 Mb, 19.099 genes in total) codes
for about 1000 G-protein coupled receptors (GPCRs) [1].
About 100 of these encode neuropeptide GPCRs [2].
The best known neuropeptide family in invertebrates is the
family of FMRFamide-related peptides (FaRPs). In C. ele-
gans, a lot of FaRPs and their corresponding receptors remain* Corresponding author. Fax: +32-16-32-39-02.
E-mail address: liliane.schoofs@bio.kuleuven.ac.be (L. Schoofs).
q Nucleotide sequence data reported are available in the GenBank
database under the Accession No. BK004131.
Abbreviations: FaRPs, FMRFamide-related peptides; ﬂp, FMRFa-
mide-like protein gene; GPCR, G-protein coupled receptor; CHO,
Chinese hamster ovary; G16, G-protein 16; Drm-sNPF-R, Drosophila
melanogaster short Neuropeptide F receptor
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in nematode parasites necessitate the identiﬁcation of new
targets and their exploitation through novel drug design.
In this study, we describe the characterization of the third
FaRP receptor in C. elegans, receptor WP:CE06880 (gene
C26F1.6). This receptor is structurally most closely related to
other orphan C. elegans GPCRs from the rhodopsin family
and the recently characterized FaRP receptors in Drosophila
melanogaster, the FMRFamide receptor [3] and short NPF
receptor [4].
We developed a cell line (HEK293 cells) expressing the
C26F1.6 orphan receptor and screened several synthetic
FaRPs, mined from the C. elegans genome, for a calcium re-
sponse in the receptor expressing cells using a cellular ﬂuo-
rescent assay. We show that two peptides of C. elegans ending
in M(L)VRFamide activate the cloned receptor in a speciﬁc
and dose-dependent way.2. Materials and methods
2.1. Cloning of the VRFamide receptor 1
The ORF of the C26F1.6 gene was ampliﬁed by PCR performed
on the cDNA (SuperScript First-Strand Synthesis System for RT-
PCR, Invitrogen, The Netherlands), synthetized from mRNA
(QuickPrep micro mRNA Puriﬁcation Kit, Roche, IN, USA) of
whole nematodes. Speciﬁc oligonucleotide PCR primers (Eurogentec,
Belgium) were used (forward primer 50-CAG GAT CCG CCA CCA
TGT TGC TAC TAC TCT CCC GGG-30; reverse primer 50-CAT
CTA GAG ACA AAT TCC TAG ATA TCA CAT GGC-30). The
Advantage 2 PCR kit (Clontech, USA) was used under the following
PCR conditions: 94 C for 60 s and 68 C for 60 s, 68 C for 180 s
(30 cycles). The obtained PCR product was ﬁrst cloned in the pCRII-
TOPO vector using the TOPO-TA Cloning kit (Invitrogen, The
Netherlands). After selection and sequencing (310 Genetic Analyzer,
Applied Biosystems, UK), the receptor was directionally cloned into
the pcDNA3 mammalian expression vector (Invitrogen).2.2. Creation of a cell line expressing C. elegans VRFa receptor 1
Human embryonic kidney (HEK293) cells were cultured at 37 C
in a humiﬁed atmosphere of 5% CO2 in DMEM (BioWhittaker,
Belgium), supplemented with 10% heat inactivated horse serum, non-
essential amino acids, 100 U/ml penicillin and 100 lg/ml streptomy-
cin. The C26F1.6/pcDNA3 construct was transfected into the
HEK293 cells using FuGene 6 (Roche, IN, USA) according to the
manufacturer’s instructions. The promiscuous G-protein Ga16 was
cotransfected.blished by Elsevier B.V. All rights reserved.
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All peptides were either custom-synthesized (Invitrogen) or made in
house using conventional Fmoc chemistry.
2.4. Fluorescence assay
The HEK293 cells were detached 24 h after transfection. Cells were
subsequently plated out in 96-well plates at approximately 70%
conﬂuence. Forty-eight hours after transfection, the cells were loaded
with ﬂuorophore, Fluo-4-AM (Molecular probes, The Netherlands)
for 1 h, after which excess ﬂuorophore was washed away with HBSS*
buﬀer (HBSS, supplemented with 5 mM CaCl2 and 10 mM HEPES).
Excitation of the ﬂuorophore was done at 488 nm. Fifty microliters
of the diﬀerent concentrations of the synthetic peptides, diluted in
HBSS* buﬀer, was pipetted out of the compound plate and added to
the 96-well plate containing the HEK-cells. The calcium response was
measured for 2 min at 525 nm using the FLEXStation (Molecular
Devices). Data were analyzed using Softmax Pro (Molecular
Devices).3. Results
3.1. Cloning of the full-length cDNA of C. elegans VRFa-R1
PCR ampliﬁcation of the cDNA with oligonucleotide
primers speciﬁc for the predicted ORF of C26F1.6 produced a
single product of approximately 1100 bp (data not shown).
Sequence determination of the TA-cloned PCR-product re-
vealed a DNA insert of 1083 bp, corresponding to the se-
quence of the ﬁve predicted exons of the C26F1.6 gene
(www.wormbase.org). The deduced protein encoded by the
ORF of the C26F1.6 gene is 360 amino acids long. Analysis by
the TMHMM program (www.cbs.dtu.dk/services/TMHMM-
2.0/) revealed that this protein is predicted to have seven
transmembrane domains along with the intracellular and ex-
tracellular loops, consistent with the known structure of
GPCRs. The N-terminal extracellular region exhibits no O-
glycosylation (www.cbs.dtu.dk/services/NetOGlyc/) and no N-
glycosylation sites (www.cbs.dtu.dk/services/NetNGlyc/). The
intracellular C-terminal region exhibits 10 possible phosphor-
ylation sites (www.cbs.dtu.dk/services/NetPhos/).
A phylogenetic tree based on Clustal W alignment of the
receptor sequence and various other related orphan C. ele-
gans GPCRs as well as the FMRFamide receptor and the
sNPF receptor of D. melanogaster, indicates that the receptor
is most closely related to C. elegans orphan receptors
CE29348 (T19F4.1) and CE06168 (K10C8.2) and to the
Drm-FMRFa (CG2114) and Drm-sNPF receptors (CG7395)
(Fig. 1). Sequence similarity among these receptors is de-
picted in their alignment by the AlignX program (Informax)
(Fig. 2).Fig. 1. Phylogenetic relationship of the C. elegans VRFamide receptor 1 (
CG7395: Drm-sNPF-R or Drosophila short NPF receptor; CG2114: Drm-
K06C4.9, K06C4.8, F21C10.12, C54A12.2, R12C12.3: predicted orphan neu3.2. Fluorescence assay
Following successful cloning of the receptor and the con-
struction of a cell line expressing the C26F1.6 gene, the cells
were challenged with diﬀerent synthetic FaRPs from D. mel-
anogaster (sNPFs and FMRFamides), and from other ar-
thropods as well as predicted peptides mined by BLAST
analysis from the genome of C. elegans (Table 1). Only two
peptides were able to clearly activate the receptor in a dose-
dependent way: TPMQRSSMVRFamide encoded by the ﬂp 7
precursor gene and AMRNALVRFamide encoded by the ﬂp
11 precursor gene. Both peptides have the M(orL)VRFamide
carboxyterminal sequence in common. Fig. 3 shows the ﬂuo-
rescence response of TPMQRSSMVRFamide, the most potent
peptide (EC50¼ 1.02 ± 0.24 lM) and the response of AM-
RNALVRFamide, the second active peptide (EC50¼
1.34 ± 0.41 lM).
The receptor response appears to be rather speciﬁc because
the EC50 value of SPMQRSSMVRFamide, which diﬀers only
by a single N-terminal amino acid from the most potent pep-
tide, is higher than 1.598 lM because at a concentration of 10
lM, a plateau is still not yet reached (Fig. 3). The EC50 value
of SPMERSAMVRFamide, another closely related peptide, is
higher than 1.732 lM (Fig. 3) and SPMDRKMVRFamide
was no longer capable to activate the receptor at all (Fig. 3).
ASGGMRNALVRFamide has the same C-terminus as the
active AMRNALVRFamide peptide, but, in contrast, is not
capable to elicit a response (Fig. 3). The receptor encoded by
the C26F1.6 gene was named the ﬁrst C. elegans VRFamide
receptor or C. elegans VRFa-R1.
To search for the minimum core sequence for receptor acti-
vation, we tested an N-terminally truncated series of synthetic
analogs of the most active peptide (TPMQRSSMVRFamide).
Deletion of the N-terminal threonine yields a peptide with an
EC50 value of 0.652 0.083 lM, which is therefore more potent
than the full-length peptide, but is still less potent than the
carboxyterminal 5-mer. Further truncation of the proline yields
an inactive peptide. The C-terminal SMVRFamide sequence
seems to be the minimum core peptide sequence required for
full activation of the receptor. This 5-mer is far more potent
than the full-length peptide sequence (EC50 value¼ 0.096±
0.016 lM).Without the interference of the N-terminal residues,
the carboxyterminal SMVRFamide (and SSMVRFa) itself is
apparently able to interact with the binding pocket region and
to elicit a maximum receptor response. For activation of the
receptor by the entire peptide sequence as predicted in the ge-
nome, the proline residue is needed to have the right confor-
mational properties to bind the receptor.C26F1.6) and related peptide receptors (AlignX software-Informax).
FMRFa-R or Drosophila FMRFamide receptor; K10C8.2, T19F4.1,
ropeptide GPCRs in C. elegans.
Fig. 2. Amino acid sequence alignments. Alignment of amino acid sequences of the C. elegans VRFamide receptor 1, C. elegans orphan GPCRs
CE29348 and CE06168, the short Neuropeptide F receptor and the FMRFamide receptor of Drosophila melanogaster by AlignX software (Infor-
max). Identical amino acids are indicated by the black background.
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BLAST searches of the C. elegans database reveal over 1000
GPCRs. Fifty-four of these receptors display similarities to
vertebrate neuropeptide receptors and may include FaRP re-
ceptors [5]. To date, only two neuropeptide receptors havebeen identiﬁed in C. elegans, namely the FLP15 peptide re-
ceptor and the AF9 receptor 1 [6,7].
We decided to search for the ligand and the function of the
C26F1.6 encoded receptor because this receptor shows very
high similarity to the recently characterized Drosophila short
neuropeptide F (sNPF) receptor [4] and the FMRFamide
Table 1
Peptide library of synthetic peptides, amino acid sequences and activity as tested in various concentrations (104–1011 M) for a calcium response
using the ﬂuorescence assay
Peptide Sequence EC50 (lM)
C. elegans peptides
ﬂp-1 KPNFMRYamide n.a.
PNFLRFamide n.a.
ﬂp-2 SPREPIRFamide n.a.
ﬂp-3 SPLGTMRFamide n.a.
ﬂp-4 PTFIRFamide n.a.
ﬂp-6 KSAYMRFamide n.a.
ﬂp-7 TPMQRSSMVRFamide 1.015 0.240
SPMQRSSMVRFamide >1.598
SPMERSAMVRFamide >1.732
SPMDRSKMVRFamide n.a.
ﬂp-10 QPKARSGYIRFamide n.a.
ﬂp-11 AMRNALVRFamide 1.336 0.414
ASGGMRNALVRFamide n.a.
NGAPQPFVRFamide n.a.
ﬂp-13 ASSAPLIRFamide n.a.
ﬂp-14 KHEYLRFamide n.a.
ﬂp-15 RGPSGPLRFamide n.a.
ﬂp-16 AQTFVRFamide n.a.
ﬂp-18 DVPGVLRFamide n.a.
CE18432 EIVFHQISPIFFRFamide n.a.
SLLDYRFamide n.a.
D. melanogaster peptides
sNPF-1 AQRSPSLRLRFamide n.a.
sNPF-2 SPSLRLRFamide n.a.
sNPF-3 PQRLRWamide n.a.
sNPF-4 PMRLRWamide n.a.
FMRFa-1 DPKQDFMRFamide n.a.
FMRFa-2 TPAEDTMRFamide n.a.
FMRFa-3 SDNFMRFamide n.a.
FMRFa-4 SPKQDFMRFamide n.a.
FMRFa-5 PDNFMRFamide n.a.
Other related peptides
Pev SK AGGSGGVGGEYDDYGHLRFamide n.a.
Scg-FLRFa PDVDHVFLRFamide n.a.
Trunctated series of most active peptide
PMQRSSMVRFamide 0.652 0.083
MQRSSMVRFamide n.a.
QRSSMVRFamide n.a.
RSSMVRFamide n.a.
SSMVRFamide 1.101 0.212
SMVRFamide 0.096 0.016
MVRFamide n.a.
n.a., not active up to 10 lM. The Y residues of the sulfakinin indicated in bold are sulfated. sNPF, short Neuropeptide F. Pev SK, Penaeus vennamei
sulfakinin. Scg-FLRFa, Schistocerca gregaria FLRFamide.
EC50 values were calculated using the results of three independent measurements. When the plateau was not reached at 10 lM, EC50 values are higher
than the calculated value.
The receptor expressing cells were incubated at 37 C post-transfection.
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sNPFs are members of the FaRP family. Since there are
no peptides with the typical sNPF structure present in the
C. elegans genome, we screened the receptor with all the dif-
ferent types of C. elegans FaRPs known to date.
The receptor speciﬁcity seems to be determined by the con-
formation of the entire peptide sequence, as indicated by the
activity proﬁle of closely related peptides. The presence of the
N-terminal residues MQR of the truncated analogs appears to
interfere with the ability of the C-terminal region to adapt to
the right conformation to bind the receptor. So we can con-
clude that N-terminal extension of the C-terminal 5-mer
(SMVRFamide) decreases receptor activation. It is hard to tellwhether either (S)SMVRFamide or TPMQRSSMVRFamide is
the endogenous ligand of the VRFamide receptor, as long as
the endogenous peptide has not been puriﬁed. Bioinformatic
analysis predicts the occurrence of TPMQRSSMVRFamide
although it may be possible that this peptide is further pro-
cessed to yield the shorter and fully potent SMVRFamide.
Flp-genes encode a family of peptides ending in RFamide,
which belong to the FMRFamide-related peptide family
(FaRPs). The ﬁrst FaRP, the genuine FMRFamide, was iso-
lated in 1977 as a cardioactive agent on the molluscan heart [8].
Since then, FARPs have been found in the nervous system of
animals representing all major phyla [9–12]. These peptides
have been shown to have diverse functions in invertebrates
Fig. 3. Dose–response curves of the most important peptides tested on the VRFamide receptor 1 expressed in HEK293 cells. Fluorescent responses of
the cloned cell line expressing the VRFa-R1 are expressed in % activation. Receptor responses (pcDNA/receptor) are represented by s and negative
control responses (pcDNA3) are represented by . These are the collected data of three independent measurements. The vertical bars represent
standard deviations. Data were processed using Softmax Pro software (Molecular Devices).
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[14,15] and neuromodulation [16]. In vertebrates, they have
anti-opioid eﬀects [17].
The 23 C. elegans ﬂp-genes, designated ﬂp-1 through ﬂp-23,
which encode 59 distinct FMRFamide-related neuropeptides,
were identiﬁed by computional methods, i.e. through con-
ventional screens of the cDNA libraries by GENEFINDER
predictions from the C. elegans Genome Consortium and
BLAST screens of the C. elegans genome [1]. C. elegans
FaRPs are expressed in at least 10% of the neurons, including
motor, sensory, and interneurons that are involved in
movement, feeding, defecation and reproduction [6]. Hill
et al. [13] made a transcriptional proﬁling of C. elegans in
which the expression of all the genes is monitored by oligo-
nucleotide arrays. They showed that there was no signiﬁcant
variation in the frequency in the transcript of genes F49E10.3
and K02G10.4 (ﬂp-7 and ﬂp-11 precursor) across eight de-
velopmental stages. The same results were found for the ex-
pression of the VRFamide receptor 1.
Out of all the ﬂp-genes, only ﬂp-1 is extensively studied. The
cognate ligands of the here described VRFamide receptor 1,
TPMQRSSMVRFa and AMRNALVRFa, respectively, en-
coded by the ﬂp-7 and ﬂp-11 precursor, are expressed in
C. elegans, since cDNAs were isolated for ﬂp-7 and EST se-
quences were found for ﬂp-11. Also, alternative transcripts
were isolated for ﬂp-11. One ﬂp-11 transcript encodes three
FaRPs, while the other transcript encodes only two of these
FaRPs [5]. The functional consequences of these alternative
transcripts are unknown. Animals in which the coding region
of the ﬂp-7 and ﬂp-11 peptide precursor genes has been deleted,
neither display an observable phenotype [18]. However, in
nematodes in particular, it has been reported that FaRPergic
neurons innervate essentially all muscular systems [19]. In
Ascaris suum, AMRNALVRFamide induces a shortening of
the ovijector, coupled with an increase in contraction fre-
quency [17]. The neuropeptides encoded by ﬂp-7 produce pa-
ralysis and loss of waveforms, increased body length and
decreased cAMP concentrations in Ascaris [20].
A genome-wide RNAi-study has recently been conducted in
C. elegans. Disruption of VRFamide receptor 1 gene (C26F1.6)
revealed no visible phenotype considering viability, growth
defects and defects in post-embryonic development [18].
However, when reproduction is considered, Keating and
coworkers [21] very recently found that RNAi of the presently
identiﬁed VRFamide receptor 1 on N2 animals resulted in a
statistically signiﬁcant increase in the number of progeny
counted 48 h post-L4. The precise mechanism underlying the
RNAi eﬀects on egg laying and brood size were not determined
in the latter study. One way of explaining the phenotype,
considering the possible role of FaRPs, one of which is the
ligand for the VRFa receptor 1, in muscle control, could be
that the increase in progeny is due to physiological changes in
the neurons or muscles that control egg laying. Future exper-
iments will have to prove this assumption, since the observed
phenotype could also be due to changes in the rate of ovula-
tion, the number of sperm in the spermatheca or microchanges
in the worm’s anatomy.It is worth noting that in this study, we described the
characterization of the third C. elegans GPCR. A lot of
orphan GPCRs await their characterization, which seems to
be an arduous task, since the big publication boom is still
to come.
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